41994-50-7

Usage

Uses

Used in Pharmaceutical Industry:
Diethyl pyrrolidine-2,5-dicarboxylate is used as a prodrug for L-proline, an essential amino acid, for its potential applications in the development of drugs for treating neurodegenerative disorders and cognitive impairments. Its ability to enhance the bioavailability and effectiveness of L-proline makes it a valuable component in the formulation of pharmaceuticals targeting these conditions.
Used in Medicinal Chemistry Research:
Diethyl pyrrolidine-2,5-dicarboxylate is used as a research compound for its antioxidant and neuroprotective properties. Its potential to protect neurons from oxidative stress and other harmful factors makes it a promising candidate for the development of novel therapeutic agents in the field of medicinal chemistry.
Used in Drug Development:
Diethyl pyrrolidine-2,5-dicarboxylate is used as a key component in the development of drugs targeting neurodegenerative disorders and cognitive impairments. Its ability to modulate the synthesis of proteins and support neuronal function makes it a valuable asset in the creation of innovative pharmaceuticals aimed at improving the quality of life for patients suffering from these conditions.

InChI:InChI=1/C10H17NO4/c1-3-14-9(12)7-5-6-8(11-7)10(13)15-4-2/h7-8,11H,3-6H2,1-2H3

Upstream product

• 17740-40-8 diethyl meso-1-benzyl-2,5-pyrrolidinedicarboxylate 
• 869-10-3 diethyl 2,5-dibromoadipate 

Downstream Products

• 90513-64-7 1-(3-Nitro-phenylcarbamoyl)-pyrrolidine-2,5-dicarboxylic acid diethyl ester 
• 90513-63-6 1-(3-Cyano-phenylcarbamoyl)-pyrrolidine-2,5-dicarboxylic acid diethyl ester 
• 90513-53-4 1-o-Tolylcarbamoyl-pyrrolidine-2,5-dicarboxylic acid diethyl ester 
• 90513-60-3 1-(3-Chloro-phenylcarbamoyl)-pyrrolidine-2,5-dicarboxylic acid diethyl ester 
• 90513-65-8 1-(3-Trifluoromethyl-phenylcarbamoyl)-pyrrolidine-2,5-dicarboxylic acid diethyl ester 
• 90513-62-5 1-(3-Fluoro-phenylcarbamoyl)-pyrrolidine-2,5-dicarboxylic acid diethyl ester 
• 90513-57-8 1-(3-Methoxy-phenylcarbamoyl)-pyrrolidine-2,5-dicarboxylic acid diethyl ester 
• 287925-06-8 6-hydroxymethylpiperidine-2-carboxylic acid 
• 52832-46-9 2-cyclohexyl-1,3-dioxo-hexahydro-pyrrolo[1,2-c]imidazole-5-carboxylic acid 
• 52886-53-0 estere etilico dell'acido-2-fenil-2,3,5,6,7,7a-esaidro-1,3-dioxo-1H-pirrolo<1,2-c>imidazolo-5-carbossilico 
• 5626-66-4 2,5-dihydroxymethylpyrrolidine 
• 67571-90-8 3-benzyl-3,8-diazabicyclo[3.2.1]octane 
• 90513-54-5 1-m-Tolylcarbamoyl-pyrrolidine-2,5-dicarboxylic acid diethyl ester 
• 53300-95-1 [3-butyl-2-(3,4-dimethyl-benzyl)-1,4-dioxo-octahydro-pyrrolo[1,2-a]pyrazin-6-yl]-acetic acid 

Relevant academic research and scientific papers

Tetracyclic pyrimidinone compound, preparation method, composition and application thereof

A tetracyclic pyrimidinone compound represented by a formula (I) or a pharmaceutically acceptable salt thereof has a structure represented by a formula (I), is a brand new Lp-PLA2 inhibitor, and can be used for treating neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis and thelike.

N-benzenesulfonyl L-proline compounds as bradykinin antagonists

This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein X1 and X2 are halo; R1 andR2 are independently hydrogen or C1-4 alkyl; R3 and R4 are each hydrogen or halo; andR5 is(a) -C3-9 diazacycloalkyl optionally substituted with C5-11 azabicycloalkyl;(b) -C3-9 azacycloalkyl-NH-(C5-11 azabicycloalkyl optionally substituted with C1-4 alkyl);(c) -NH-C1-3 alkyl-C(O)-C5-11 diazabicycloalkyl;(d) -NH-C1-3 alkyl-C(O)-NH-C5-11 azabicycloalkyl, the C5-11 azabicycloalkyl being optionally substituted with C1-4 alkyl;(e) -C3-9 azacycloalkyl optionally substituted with C3-9 azacycloalkyl; or(f) -NH-C1-5 alkyl-NH-C(O)-C4-9 cycloalkyl-NH2. These compounds are useful for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.

COMPOUNDS THAT MODULATE ENDOTHELIN ACTIVITY

Compounds of formula (I) and pharmaceutical compositions containing the compounds of formula (I): STR1 are provided. In formula (I): Ar is a substituted or unsubstituted aromatic or heterocyclic group; R is H or a substituted or unsubstituted straight or branched chain, cyclic or mixture of straight branched and cyclic alkyl, alkenyl, or alkynyl group having from 1-20 carbon atom; A is a functional group that bears a polar moiety; R 1 is R, R--C=0, R substituted with one or more heteroatoms, a substituted or unsubstituted aryl group, or is aryl-(CH 2) n ; R 2 is (CH 2) n, CHR, C(R) 2, COO, OCO, NHCO, CONH, SO, SO 2 or NR; R 3 and R 4, which are the same or different or each may be absent, and are =O, H, O-aryl, OR, O-alkyl or alkyl, aryl, SR, S-aryl, NHR, NH-aryl, NR, or are other heteroaromatic groups; R 5 is H, OH or R; E and F, which are the same or are different, are either N or (CH 2) p ; p is an integer or 0 between 0 and 5; m and n are integers or 0 between 0 and 10; T is O, S, NCOR or NR; U and V, which may be the same or different, are (CH. sub.2) n; W is CO, (CH 2)n, (CH 2) n--CHR or CHR--(CH 2) n ; X and Y, which may be the same or different, are H, alkyl or aryl or X and Y form a saturated or unsaturated homocyclic or heterocyclic ring contain 3-15 members; and Z is H, SR, NHR or N(R) 2.